Drug Trial Radar · NCT02515656
Assessment of the Efficacy of POLYGYNAX® in the Empirical Treatment of Infectious Vaginitis
Last checked: Nov 19, 2026Latest source record: Jan 22, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
661
Actual
Start
Sep 2015
Primary completion
Aug 2016
Study completion Aug 2016
Sponsor
- Lead sponsor
- Laboratoire Innotech InternationalIndustry
- Sponsor type
- Industry
- Collaborators
- International Clinical Trials Association; Venn Life Sciences
- First posted
- Aug 5, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
POLYGYNAX® is a broad spectrum combination of nystatin, neomycin and polymixin B indicated for the local treatment of vaginitis due to sensitive germs and treatment of non specific vaginitis of adults. POLYGYNAX® has been marketed in France since 1969. Nevertheless, despite the well established use of POLYGYNAX®, there is no clinical study supporting the interest of the combination of antifungal and antibiotics agents versus antifungal agent alone. The aim of this project is to demonstrate that POLYGYNAX® is more effective than miconazole in the treatment of women experiencing symptoms of infectious vaginitis.
Conditions
- Vaginitis
Interventions
POLYGYNAX®Drug
GYNODAKTARIN®Drug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Treatment Efficacy Assessed by the Investigator After Thorough Gynaecological Examination and Patient's Interview at End of Treatment VisitTime frame: 15 days after first treatment administration
Locations
4 sites in 4 countries. Site status is shown where the registry gives one.
TURKOVA
Prague, Czechia
PERCEVAL
Lyon, France
MARICIC
Belgrade, Serbia
GATOVA
Martin, Slovakia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.